WO1992004014A3 - Regulation de la proliferation de cellules neoplasiques par l'intermediaire d'un nouveau recepteur 5ht1a - Google Patents

Regulation de la proliferation de cellules neoplasiques par l'intermediaire d'un nouveau recepteur 5ht1a Download PDF

Info

Publication number
WO1992004014A3
WO1992004014A3 PCT/US1991/006175 US9106175W WO9204014A3 WO 1992004014 A3 WO1992004014 A3 WO 1992004014A3 US 9106175 W US9106175 W US 9106175W WO 9204014 A3 WO9204014 A3 WO 9204014A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell proliferation
regulation
novel
neoplastic cell
5ht1a receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1991/006175
Other languages
English (en)
Other versions
WO1992004014A2 (fr
Inventor
Thomas Martin Aune
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Miles Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miles Inc filed Critical Miles Inc
Publication of WO1992004014A2 publication Critical patent/WO1992004014A2/fr
Publication of WO1992004014A3 publication Critical patent/WO1992004014A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Procédé de régulation de la prolifération de cellules néoplasiques présentant un récepteur 5HT1a, consistant à introduire une quantité suffisante d'agonistes ou d'antagonistes pour accroître ou réduire la prolifération cellulaire. La prolifération cellulaire peut être régulée (1) par l'intermédiaire du récepteur 5HT et/ou (2) par l'intermédiaire de l'inhibition de la synthèse de la sérotonine.
PCT/US1991/006175 1990-09-04 1991-09-04 Regulation de la proliferation de cellules neoplasiques par l'intermediaire d'un nouveau recepteur 5ht1a Ceased WO1992004014A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57871090A 1990-09-04 1990-09-04
US578,710 1990-09-04

Publications (2)

Publication Number Publication Date
WO1992004014A2 WO1992004014A2 (fr) 1992-03-19
WO1992004014A3 true WO1992004014A3 (fr) 1992-05-14

Family

ID=24313971

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1991/006176 Ceased WO1992004015A2 (fr) 1990-09-04 1991-09-04 REGULATION DE LA PROLIFERATION DE LYMPHOCYTES T VIA UN NOUVEAU RECEPTEUR, LE 5HT1a
PCT/US1991/006175 Ceased WO1992004014A2 (fr) 1990-09-04 1991-09-04 Regulation de la proliferation de cellules neoplasiques par l'intermediaire d'un nouveau recepteur 5ht1a

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US1991/006176 Ceased WO1992004015A2 (fr) 1990-09-04 1991-09-04 REGULATION DE LA PROLIFERATION DE LYMPHOCYTES T VIA UN NOUVEAU RECEPTEUR, LE 5HT1a

Country Status (5)

Country Link
EP (2) EP0555231A1 (fr)
JP (2) JPH06500775A (fr)
AU (2) AU8848291A (fr)
CA (2) CA2090689A1 (fr)
WO (2) WO1992004015A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5461054A (en) * 1993-12-09 1995-10-24 Bayer Aktiengesellschaft Anthracene-spiro-pyrrolindines
US5411960A (en) * 1993-12-09 1995-05-02 Bayer Aktiengesellschaft Substituted pyrroloanthracenes and -diones
US5409932A (en) * 1993-12-09 1995-04-25 Bayer Ag Piperazine-substituted pyrroloanthracenes
WO1996001106A1 (fr) * 1994-07-06 1996-01-18 Bo Arne Hofmann Emploi d'agents pharmaceutiques pour attenuer ou traiter la dysfonction immunitaire liee a l'infection par le vih ou des virus associes
AU2880595A (en) * 1994-07-06 1996-01-25 Bo Arne Hofmann Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
EP0813878B1 (fr) * 1996-06-17 2002-02-06 Mitsubishi Chemical Corporation Agent pour accélérer la lacrimation contenant un ligand de la sérotonine, particuliérement un composé aminoalkoxybibenzyle
AU2002305123B2 (en) 2001-03-30 2006-10-05 Philadelphia Health And Education Corporation Immunomodulation and effect on cell processes relating to serotonin family receptors
CA2683316A1 (fr) * 2007-04-13 2009-02-19 Southern Research Institute Agents anti-angiogeniques et procedes d'utilisation
AU2021337864A1 (en) * 2020-09-02 2023-05-04 Yztherapeutic Performance Ltd. Cellular composition for treatment of diseases, disorders or conditions and method of use
CN113599370B (zh) * 2021-08-03 2023-12-08 复旦大学附属肿瘤医院 8-oh-dpat及其衍生物在制备抗肿瘤药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002527A1 (fr) * 1989-08-21 1991-03-07 Beth Israel Hospital Association Procede et composition de traitement d'hypersensibilite cutanee, oculaire et des muqueuses, d'etats inflammatoires et hyperproliferatifs en utilisant des preparations topiques d'antagonistes de serotonine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002527A1 (fr) * 1989-08-21 1991-03-07 Beth Israel Hospital Association Procede et composition de traitement d'hypersensibilite cutanee, oculaire et des muqueuses, d'etats inflammatoires et hyperproliferatifs en utilisant des preparations topiques d'antagonistes de serotonine

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Cancer Research, vol. 48, no. 15, 1 August 1988, (Philadelphia, US), T. MANDA et al.: "Important role of serotonin in the antitumor effects of recombinant human tumor necrosis factor-alpha in mice", pages 4250-4255, see the abstract *
European Journal of Pharmacology, vol. 170, no. 1/2, October 1989, (Amsterdam, NL), M.R. PRANZATELLI et al.: "Identification of 5-HT1A recognition sites in human ganglioneuroblastoma", pages 127-128, see the whole document *
Nature, vol. 335, 22 September 1988, (London, GB), A. FARGIN et al.: "The genomic clone G-21 which resembles a beta-adrenergic receptor sequence encodes the 5-HT1A receptor", pages 358-360, see page 359, right-hand column, lines 1-14; figure 4; table 1 (cited in the application) *
New England Journal of Medicine, vol. 277, no. 21, 1967, (Boston, US), K. ENGELMAN et al.: "Inhibition of serotonin synthesis by para-chlorophenylalanine in patients with the carcinoid syndrome", pages 1103-1108, see the abstract *
Proceedings of the National Academy of Sciences of USA, vol. 81, no. 6, March 1984, (Washington, DC, US), P. DANNIES et al.: "Spiperone: Evidence for uptake into secretory granules", pages 1867-1870, see the whole document *
The Merck Index, 11th edition (Eds. S. BUDAVARI et al.), 1989, Merck & Co., Rahway, NJ, US, see no 6097. Mianserin; no. 8707. Spiperone *

Also Published As

Publication number Publication date
JPH06503816A (ja) 1994-04-28
JPH06500775A (ja) 1994-01-27
WO1992004015A2 (fr) 1992-03-19
CA2090688A1 (fr) 1992-03-05
AU8848291A (en) 1992-03-30
EP0555231A1 (fr) 1993-08-18
WO1992004014A2 (fr) 1992-03-19
WO1992004015A3 (fr) 1992-04-16
AU8499891A (en) 1992-03-30
CA2090689A1 (fr) 1992-03-05
EP0547172A1 (fr) 1993-06-23

Similar Documents

Publication Publication Date Title
MD1616F2 (en) Tricyclic compounds and method of inhibiting the tyrasin kinases receptors of the epidermal growth factor, pharmaceutical composition, methods of preventing the blastocites implantation and mammals treatment
EP0615949A3 (fr) Dispositif pour la production d'hydrogène.
MD1632F2 (en) Bicyclic compounds, method of inhibiting the tyrosine kinases receptors as epidermal growth factor, pharmaceutical composition, methods of preventing blastocyte implantation and treatment of mammals
ES8801900A1 (es) Un procedimiento para la preparacion de derivados de indol
ATE238771T1 (de) Herstellungsverfahren von löslichen verabreichungssystemen unter verwendung von flüchtigen salzen
AU560028B2 (en) Pyridine-n-oxide derivatives
MY131298A (en) 5-heteroyl indole derivatives
EG19322A (en) 1-(0-cyclopropylcarbonyl phenyl sulfamoyl) 3-(4,6-dimethoxy-2-pyrimidinyl) ure and method for the preparation there of
AU6944091A (en) Indole-substituted five-membered heteroaromatic compounds
WO1992004014A3 (fr) Regulation de la proliferation de cellules neoplasiques par l'intermediaire d'un nouveau recepteur 5ht1a
MY118556A (en) Catalytic composition suitable for the fischer-tropsch process
EP0354777A3 (fr) Dérivés du 3-(4-pipéridine)-5-(2-sulfonylaminoéthyl)-indole
EP0351112A3 (fr) Composé photochromique, procédé de préparation, son application et composition photochromique le contenant
ATE73110T1 (de) Kieselsaeuren.
AU8979191A (en) 3,7-disubstituted indole derivatives
MY113266A (en) New indol derivatives derivatives with high affinity 5-ht1a receptor.
ATE200089T1 (de) Dimerdiol-modifizierte uretdion- pulverlackvernetzer
AU2999684A (en) Substituted 2-(monoannelated (3,4-, 4,5- and 5,6-) pyridylalkylenesulfinyl)-benzimidazoles
GR3031802T3 (en) Positive photoactive compounds based on 2,6-dinitrobenzyl groups
EP0440086A3 (en) Radiation-sensitive composition, radiation-sensitive recording material produced therewith and process for the production of relief records
NO911490L (no) Fremgangsmaate for hydrogenperoksydbleking av papirmasse, med hoeyt utbytte.
MX9801133A (es) Agente endoparasiticida a base de didepsipeptidos, nuevos didepsipeptidos y procedimiento para su produccion.
AU566900B2 (en) 2,3-dihydro-3-oxo-1h-isoindole derivatives
EP0485890A3 (en) Use of 2,3-disubstituate 1-azolyl-propane for inhibiting the pathogenic growth phase of dimorph yeast cell
EP0442386A3 (en) Radiation-sensitive composition, radiation-sensitive recording material produced therewith and process for the production of relief records

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

COP Corrected version of pamphlet

Free format text: PAGES 8-12,18,28,44,DESCRIPTION AND PAGES 1/23,4/23,6/23-8/23,10/23-12/23,14/23-16/23,19/23-23/23,DRAWINGS,REPLACED BY NEW PAGES BEARING THE SAME NUMBER;AFTER THE RECTIFICATION OF OBVIOUS ERRORS AS AUTHORIZED BY THE UNITED STATES PATENT AND TRADEMARKS OFFICE IN ITS CAPACITY AS INTERNATIONAL SEARCHING AUTHORITY

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1991915814

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2090688

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1991915814

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991915814

Country of ref document: EP